eramkafusp alfa (IGN002) / Assertio - LARVOL DELTA

[VIRTUAL] IGN002 (antiCD20-IFNα2b) intravenously administered tumor targeted delivery of IFNα2b and its effects in Non-Hodgkin Lymphoma (TAT 2021) - "Conclusions IGN002 demonstrated adequate stability in the tumor resulting in the reduction in tumor mass and increased survival when compared to rituximab. Thus, demonstrating that the targeted delivery of IFNα2b to CD20+ tumor warrants further investigation in NHL patients."

Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

[VIRTUAL] A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Intravenous Doses of IGN002 Administered Weekly to Subjects with Refractory Non-Hodgkin Lymphoma (ASH 2020) - P1 | "The mAb portion of IGN002 is a chimeric IgG1 antibody with the same amino acid sequence as rituximab. Target Accrual:In the Dose-Escalation Stage and Expansion Stage, approximately 9-18 (~3-6 subjects per cohort) and 14 subjects, respectively, will be accrued. Enrollment for Cohort 6 is expected to commence in September 2020."

Clinical • P1 data • PK/PD data • Hematological Malignancies • Lymphoma • Mediastinal B Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

A Study of IGN002 for Refractory NHL (clinicaltrials.gov) - P1 | N=0 | Withdrawn | Sponsor: Spectrum Pharmaceuticals, Inc | N=62 ➔ 0 | Not yet recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Phase 1, Dose-Escalation Study of IGN002 in NHL Subjects (clinicaltrials.gov) - P1 | N=62 | Terminated | Sponsor: Spectrum Pharmaceuticals, Inc | Recruiting ➔ Terminated; Strategic Reasons

Trial termination • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD20

Phase 1, Dose-Escalation Study of IGN002 in NHL Subjects (clinicaltrials.gov) - P1; N=62; Recruiting; Sponsor: Spectrum Pharmaceuticals, Inc; Suspended ➔ Recruiting

Enrollment open • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD20

[VIRTUAL] IGN002 (antiCD20-IFNα2b) intravenously administered tumor targeted delivery of IFNα2b and its effects in Non-Hodgkin Lymphoma (TAT 2021) - "Importantly, the most frequently mutated genes in metastatic tumors were TP53 (100% of cases) and PTPRT (75% of cases). Conclusions Taken together, our findings indicate that metastatic LUSC associated with isolated BCH shows a highly mutable phenotype."

Hematological Malignancies • Lung Cancer • Lymphoma • Non Small Cell Lung Cancer • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor • Squamous Cell Carcinoma • MMP1 • MMP2 • RB1 • TP53

Spectrum Pharmaceuticals Announces Two Presentations at Upcoming ESMO TAT Virtual Congress 2021 (Businesswire) - “Spectrum Pharmaceuticals…announced two presentations, one oral and one eposter, at the upcoming European Society for Medical Oncology Targeted Anticancer Therapies (ESMO TAT) Virtual Congress 2021. The oral presentation will provide some initial safety and efficacy data for poziotinib from the twice daily dosing cohort. The meeting takes place on March 1 – 2, 2021…Title: IGN002 (antiCD20-IFNα2b) intravenously administered tumor targeted delivery of IFNα2b and its effects in non-Hodgkin lymphoma…Presentation Number: #20P (poster) Title: Safety, tolerability and preliminary efficacy of poziotinib with twice daily strategy in EGFR/HER2 Exon 20 mutant non-small cell lung cancer”

Clinical data • Hematological Malignancies • Lung Cancer • Non Small Cell Lung Cancer • Non-Hodgkin’s Lymphoma • Oncology

Phase 1, Dose-Escalation Study of IGN002 in NHL Subjects (clinicaltrials.gov) - P1; N=62; Suspended; Sponsor: Spectrum Pharmaceuticals, Inc; Trial completion date: Dec 2018 ➔ Jan 2025; Recruiting ➔ Suspended; Trial primary completion date: Oct 2018 ➔ Nov 2024

Clinical • Trial completion date • Trial primary completion date • Trial suspension

A Study of IGN002 for Refractory NHL (clinicaltrials.gov) - P1; N=62; Not yet recruiting; Sponsor: Spectrum Pharmaceuticals, Inc; Phase classification: P2 ➔ P1; Trial completion date: Dec 2019 ➔ Dec 2025; Trial primary completion date: Dec 2019 ➔ Jul 2025

Clinical • Phase classification • Trial completion date • Trial primary completion date